Phase II
Immutep Limited announced it will pair its lead immunotherapy product with Merck’s blockbuster PD-1 inhibitor Keytruda to treat three solid tumor types in a single trial.
Realm Therapeutics announced today that its PR013, failed to show efficacy in its Phase II trial for allergic conjunctivitis.
Merrimack Pharmaceuticals announced it is expanding enrollment in a Phase II lung cancer study.
MyoKardia Inc. revealed positive results from a mid-stage obstructive hypertrophic cardiomyopathy trial.
A mid-stage program aimed at treating myelosuppression in lung cancer patients undergoing chemotherapy is yielding positive results.
A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe.
Late Thursday the companies touted biomarker data from an early-stage study that showed the drug lowered the disease-causing protein in people with the disease.
PharmaCyte Biotech recently discussed its options and plans for a Phase IIb clinical trial of its Cell-in-a-Box technology in pancreatic cancer.
Reata Pharmaceuticals has updated the timing of coming data announcements for two ongoing mid-stage trials for rare renal diseases.
Galera Therapeutics has initiated its Phase I/II clinical trial of GC4419 in locally advanced pancreatic cancer (LAPC).
PRESS RELEASES